Transcatheter Strategies for Leaflet Extension to Treat Mitral Regurgitation
经导管小叶延伸治疗二尖瓣反流策略
基本信息
- 批准号:9754866
- 负责人:
- 金额:$ 38.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-01 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAmericanAnimal ModelAnteriorBiomedical EngineeringBloodCardiacCardiac Surgery proceduresCathetersChronicClinicalClipComplexComplicationCongestive Heart FailureDataDevelopmentDevice DesignsDevicesEchocardiographyEndotheliumEngineeringEnhancersEnvironmentFDA approvedFailureFamily suidaeFutureGeometryHeartHeart ResearchHeart ValvesHeart failureHeightImplantLeftLeft Ventricular RemodelingLengthLesionLiquid substanceMeasurementMeasuresMechanicsMedicalMitral ValveMitral Valve InsufficiencyModelingMyocardial InfarctionMyocardial IschemiaOperative Surgical ProceduresOutcomePatientsPharmaceutical PreparationsPhysiologicalPolytetrafluoroethyleneProceduresPublic HealthRecording of previous eventsRecurrenceRefluxResearch Project GrantsResidual stateRiskSafetySarinSiteSudden DeathSurfaceSurgeonSystemTechniquesTechnologyTestingThe SunTherapeuticThrombosisTimeTissuesTranslational ResearchTranslationsVentricularVentricular RemodelingWorkanimal imagingbasebiomechanical engineeringclinical practiceclinical translationdesignengineering designexperiencefeasibility trialflexibilityhealingheart functionhospitalization ratesimage guidedimprovedinnovationinsightmembermortalitymultidisciplinarynew technologynitinolnovelparallelizationpreservationprototyperepairedsafety and feasibilitysoundsuccesssurgical researchtissue stress
项目摘要
ABSTRACT/PROJECT SUMMARY
Ischemic mitral regurgitation (IMR) is reflux of blood through the mitral valve, developing in patients surviving a
myocardial infarction or chronic ischemic heart disease. 2.7 million Americans suffer from this condition and
progressively develop congestive heart failure. Their hospitalization rates are higher and they present with
significant risk of sudden death. Timely correction of IMR can halt adverse ventricular remodeling, but current
techniques to repair IMR require open-heart surgery, a risky procedure in these patients. Several transcatheter
strategies are in development, but all of them have demonstrated poor outcomes with significant remnant
regurgitation or repair failure due to procedural complexity. We hypothesized that the most effective and
durable technique to correct IMR is by extending the native leaflet lengths at the site of the regurgitation,
restoring systolic leaflet edge parallelization, so that coaptation is restored and regurgitation is effectively
eliminated. We developed a novel, flexible;; nitinol implant covered with expanded polytetrafluoroethylene,
which when deployed on the anterior or posterior mitral valve leaflet extends the leaflet shelf and restores
leaflet coaptation. The device integrates into the native leaflet with tissue encapsulation over 4-6 weeks, and
the endothelialized tissue permanently adds to the native leaflet length for IMR correction. Strong preliminary
data supporting the feasibility and safety of this concept have been generated in ex vivo and swine models. In
this R01 application, we propose to advance this concept further, with a focus on optimizing the device design
to best restore valve function and preserve valve mechanics. Three aims are proposed - (Aim 1) Optimize the
device features to achieve best IMR reduction and highest leaflet coaptation, while preserving the native valve
mechanics and fluid dynamics;; (Aim 2) investigate the durability of the device in correcting IMR in a
progressively remodeling LV, investigate chronic device healing and tissue remodeling, and measure the
thrombotic potential of the device in swine;; and (Aim 3) develop a trans-septal delivery catheter for image
guided deployment of the device on the mitral valve, and assess the safety and efficacy of this procedure in
swine. We have assembled a collaborative, multidisciplinary team with experience in biomedical device design
& engineering, computational tissue and fluid mechanics, animal models and imaging, and clinical experience
in transcatheter valve therapies, in an environment with a history of innovative cardiac research. There is high
potential for clinical translation of this technology, and the proposed work will optimize the technology and
mitigate the failure modes & risks. Completion of the proposed aims will result in a significantly better
therapeutic option to repair ischemic mitral regurgitation, which is a highly translational end-point and will
address a significant unmet clinical need.
摘要/项目摘要
缺血性二尖瓣反流(IMR)是血液通过二尖瓣反流,在存活的患者中发育
心肌梗塞或慢性缺血性心脏病。 270万美国人患有这种情况,
逐渐发展出充血性心力衰竭。他们的住院率较高,他们与
突然死亡的重大风险。及时校正IMR可以阻止心室重塑,但电流
修复IMR的技术需要开心手术,这是这些患者的冒险手术。几个经典仪
策略正在开发中,但所有这些都表现出差的结果
由于程序复杂性而导致的反流或修复失败。我们假设最有效,
校正IMR的耐用技术是通过在反流部位扩展本地小叶长度,
恢复收缩小叶边缘并行化,以便恢复仪式并有效地反流
淘汰。我们开发了一种小说,灵活的;硝基二氟乙烯覆盖的硝基醇植入物,
当部署在前或后孔瓣膜上时,它会延伸传单架并恢复
小叶仪式。该设备在4-6周内整合到本机叶中,并用组织封装,然后
内皮化组织永久增加了本地小叶长度以进行IMR校正。强大的初步
支持该概念的可行性和安全性的数据已在离体和猪模型中产生。在
这个R01应用程序,我们建议进一步推进这一概念,重点是优化设备设计
最佳恢复阀功能并保留阀门力学。提出了三个目标 - (目标1)优化
设备功能可实现最佳的IMR降低和高级传单仪式,同时保留天然阀
力学和流体动力学; (AIM 2)调查设备在校正IMR时的耐用性
逐渐重塑左室,研究慢性装置愈合和组织重塑,并测量
设备在猪中的血小板潜力; (AIM 3)开发图像的透射输送导管
该设备在二尖瓣上的指导部署,并评估该程序的安全性和有效性
猪。我们组建了一个具有生物医学设备设计经验的合作,多学科团队
&工程,计算组织和流体力学,动物模型和成像以及临床经验
在具有创新心脏研究史的环境中,经导管阀疗法中。那里很高
该技术的临床翻译潜力,拟议的工作将优化技术和
减轻故障模式和风险。拟议的目标的完成将导致更好
修复缺血性二尖瓣反流的治疗选择,这是一个高度翻译的终点,将
满足了巨大的未满足临床需求。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sai Muralidhar Padala其他文献
Sai Muralidhar Padala的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sai Muralidhar Padala', 18)}}的其他基金
Novel therapeutic approaches to Mitral valve repair in ischemic heart disease
缺血性心脏病二尖瓣修复的新治疗方法
- 批准号:
9756450 - 财政年份:2017
- 资助金额:
$ 38.49万 - 项目类别:
Transcatheter Strategies for Leaflet Extension to Treat Mitral Regurgitation
经导管小叶延伸治疗二尖瓣关闭不全的策略
- 批准号:
10001587 - 财政年份:2017
- 资助金额:
$ 38.49万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Developing Real-world Understanding of Medical Music therapy using the Electronic Health Record (DRUMMER)
使用电子健康记录 (DRUMMER) 培养对医学音乐治疗的真实理解
- 批准号:
10748859 - 财政年份:2024
- 资助金额:
$ 38.49万 - 项目类别:
Circadian control of neuroinflammation after spinal cord injury
脊髓损伤后神经炎症的昼夜节律控制
- 批准号:
10639178 - 财政年份:2023
- 资助金额:
$ 38.49万 - 项目类别:
Mentoring Emerging Researchers at CHLA (MERCH-LA)
指导 CHLA (MERCH-LA) 的新兴研究人员
- 批准号:
10797938 - 财政年份:2023
- 资助金额:
$ 38.49万 - 项目类别:
Elucidating causal mechanisms of ethanol-induced analgesia in BXD recombinant inbred mouse lines
阐明 BXD 重组近交系小鼠乙醇诱导镇痛的因果机制
- 批准号:
10825737 - 财政年份:2023
- 资助金额:
$ 38.49万 - 项目类别:
Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias
用于治疗阿尔茨海默病和相关痴呆症的天然产物化合物的新组合
- 批准号:
10603708 - 财政年份:2023
- 资助金额:
$ 38.49万 - 项目类别: